Literature DB >> 18395948

Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis.

Márcio Sobreira Silva Araújo1, Renata Aline de Andrade, Leonardo Rocha Vianna, Wilson Mayrink, Alexandre Barbosa Reis, Renato Sathler-Avelar, Andréa Teixeira-Carvalho, Mariléia Chaves Andrade, Maria Norma Mello, Olindo Assis Martins-Filho.   

Abstract

Phenotypic features of peripheral blood leukocytes have been investigated as a pre-requisite to characterize the protective immunity attributed to both Leishvaccine and Leishmune. Our results showed that either those vaccine were accompanied by distinct profiles on innate immune compartment. While Leishvaccine promoted early changes in phenotypic features of neutrophils and eosinophils with late involvement of monocytes, Leishmune induced early and persistent activation of neutrophils and monocytes, without changes on eosinophil activation status. Regarding the adaptive immunity, Leishvaccine sponsored a mixed profile, associated with phenotypic changes of T and B-lymphocytes. Major phenotypic changes in CD4+ T-cells with transient activation of CD8+ T-cell, besides decreased frequency of B-cell expressing CD32 were the hallmark of Leishvaccine. In contrast, Leishmune was associated with phenotypic changes in T-lymphocytes, particularly in CD8+ T-cells, and selective up-regulation of CD3+CD5+LowCD8+ cells. We hypothesized that this dissimilar alteration in immunological events would represent phenomenon directly related with the molecular nature of these vaccines besides the distinct adjuvants employed. However, it is important to emphasize that both immunobiologicals are able to activate phagocytes and CD8+ T-cells and therefore could be considered priority vaccines with a high-quality immunogenic potential against CVL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395948     DOI: 10.1016/j.vaccine.2008.02.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.

Authors:  Alessandra Estrela-Lima; Márcio S S Araújo; João M Costa-Neto; Andréa Teixeira-Carvalho; Stella M Barrouin-Melo; Sergio V Cardoso; Olindo A Martins-Filho; Rogéria Serakides; Geovanni D Cassali
Journal:  BMC Cancer       Date:  2010-06-04       Impact factor: 4.430

Review 2.  One Health: the global challenge of epidemic and endemic leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa; Michael J Day
Journal:  Parasit Vectors       Date:  2011-10-10       Impact factor: 3.876

3.  LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.

Authors:  Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Henrique Gama Ker; Nádia das Dores Moreira; Fernando Augusto Siqueira Mathias; Jamille Mirelle de Oliveira Cardoso; Nelder Figueiredo Gontijo; Oscar Bruna-Romero; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Rodrigo Corrêa-Oliveira; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  Parasit Vectors       Date:  2014-02-07       Impact factor: 3.876

Review 4.  Vaccines for canine leishmaniasis.

Authors:  Faeze Foroughi-Parvar; Gholamreza Hatam
Journal:  Adv Prev Med       Date:  2014-12-31

5.  Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge.

Authors:  Lucilene Aparecida Resende; Rodrigo Dian de Oliveira Aguiar-Soares; Henrique Gama-Ker; Bruno Mendes Roatt; Ludmila Zanandreis de Mendonça; Marina Luiza Rodrigues Alves; Denise da Silveira-Lemos; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Márcio Sobreira Silva Araújo; Ricardo Toshio Fujiwara; Nelder Figueiredo Gontijo; Alexandre Barbosa Reis; Rodolfo Cordeiro Giunchetti
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

Review 6.  Biomarkers Associated With Leishmania infantum Exposure, Infection, and Disease in Dogs.

Authors:  Carla Maia; Lenea Campino
Journal:  Front Cell Infect Microbiol       Date:  2018-09-06       Impact factor: 5.293

7.  Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano-Souza; Wendel Coura-Vital; Samuel Leôncio Braga; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Marta de Lana; Nelder Figueiredo Gontijo; Marcos José Marques; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

8.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

9.  Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Iam Palatnik-de-Sousa; Alexandre Morrot; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-06-11       Impact factor: 7.561

10.  The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma.

Authors:  Marília Carneiro Machado; João Moreira da Costa-Neto; Ricardo Dias Portela; Mário Jorge Melhor Heine D'Assis; Olindo Assis Martins-Filho; Stella Maria Barrouin-Melo; Natalie Ferreira Borges; Fabiana Lessa Silva; Alessandra Estrela-Lima
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.